(Source: Affimed NV) 21a0a43f-3cf1-4765-97f5-1cced1f376d4.pdf FOR IMMEDIATE RELEASE Affimed to Present Data on NK- and T-Cell Engagers at ASH Heidelberg, Germany, November 5, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical- stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that two of the Company's abstracts have been chosen for poster presentations at the 57th annual American Society of Hematology (ASH) conference, being held December 5-8, 2015 in Orlando, Florida. Poster Information Abstract #2747 Title: 'CD30/CD16A TandAb AFM13-Induced Target Cell Lysis by NK-Cells is Enhanced by CD137 Co-Stimulation and Blocking PD-1' Session Name: 625....
↧